Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Big pharma continues to walk away from investment in new antibiotics and there are alarmingly few useful new drugs in the pipeline to deal with the worsening crisis of antibiotic resistance, according to the World Health Organization.
Two reports paint a bleak picture. Efforts to discover new antibiotics are “insufficient to tackle the challenge of increasing emergence and spread of antimicrobial resistance”, says a review of clinical development.
Most antibiotics being developed are hardly any improvement on existing drugs.
The limited research that is being undertaken is generally by small or medium-sized companies, “with large pharmaceutical companies continuing to exit the field”.
There have been only eight new antibacterial agents approved since 1 July 2017, but overall, says the report, “they have limited clinical benefits”. There has been one important success story – pretomanid has been approved for patients with drug-resistant tuberculosis. But it was developed not by a pharmaceutical company but by the not-for-profit TB Alliance.
https://www.theguardian.com/busines...failing-to-invest-in-new-antibiotics-says-who
Two reports paint a bleak picture. Efforts to discover new antibiotics are “insufficient to tackle the challenge of increasing emergence and spread of antimicrobial resistance”, says a review of clinical development.
Most antibiotics being developed are hardly any improvement on existing drugs.
The limited research that is being undertaken is generally by small or medium-sized companies, “with large pharmaceutical companies continuing to exit the field”.
There have been only eight new antibacterial agents approved since 1 July 2017, but overall, says the report, “they have limited clinical benefits”. There has been one important success story – pretomanid has been approved for patients with drug-resistant tuberculosis. But it was developed not by a pharmaceutical company but by the not-for-profit TB Alliance.
https://www.theguardian.com/busines...failing-to-invest-in-new-antibiotics-says-who